Scalper1 News
Israeli drug giant Teva Pharmaceutical Industries (TEVA) reported positive results for a recently acquired drug Tuesday. Teva stock was down a fraction, however, as the company also faced a new roadblock in its effort to take over Mylan (MYL). Teva said that SD-809, a drug that it had gained in its $3.5 billion buyout of Auspex Pharmaceuticals last month, hit the primary endpoint in a pivotal trial of tardive dyskinesia, a movement disorder that Scalper1 News
Scalper1 News